My Breast And I - national surgical adjuvant breast and bowel project nsabp

Category

national surgical adjuvant breast and bowel project nsabp - My Breast And I


The National Surgical Adjuvant Breast and Bowel Project (NSABP) is a clinical trials cooperative group supported since its inception by the National Cancer Institute (NCI). We have a more than year history of designing and conducting clinical trials that have changed the way breast cancer is treated, and, more recently, prevented. The NSABP (National Surgical Adjuvant Breast and Bowel Project) Tissue Bank is the central repository of tissue samples (stained and unstained slides, tissue blocks, and frozen tissue specimens) collected from clinical trials conducted by the NSABP. The NSABP Tissue Bank is located at the NSABP Division of Pathology laboratory.

Norman Wolmark, M.D. is the Chairman of the National Surgical Adjuvant Breast and Bowel Project (NSABP), a cooperative clinical trials group funded primarily by the National Cancer Institute. Dr. Dr. Wolmark is also the Principal Investigator of the NSABP Operations Center located on the Allegheny campus of Allegheny University of the Health Sciences. The National Library of Medicine (NLM), on the campus of the National Institutes of Health in Bethesda, Maryland, is the world's largest medical library. The Library collects materials in all areas of biomedicine and health care, as well as works on biomedical aspects of technology, the humanities, and the physical, life, and social sciences.

The National Surgical Adjuvant Breast and Bowel Project (NSABP) has made significant contributions in reducing the extent of breast surgery and in improving outcomes of patients with early-stage breast cancer through the conduct of large randomized Cited by: 3. The National Surgical Adjuvant Breast and Bowel Project clinical trials group (NSABP) in partnership with University of Vermont is conducting a randomized clinical trial, B, to determine whether SNB alone will provide the same survival and long-term regional disease control as ANR in clinically node-negative breast cancer patients. 4 The primary endpoints of the B trial are Cited by: